Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Laurantis Pharma has selected Ark Therapeutics to manufacture and supply Lymfactin investigational therapy for breast cancer-associated Lymphedema.
Subscribe to our email newsletter
The agreement, whose specific terms were not disclosed, is subject to Laurantis gaining approval for Phase I trial that is scheduled to begin in 2013.
Lymfactin leverages an adenoviral vector to transport vascular endothelial growth factor during lymph node transplantation in a course to avoid lymphedema.
The Phase I trial of Lymfactin is expected to recruit patients in the US and Finland.
At present no therapeutic treatment exists to treat breast cancer-associated lymphedema, the common form of secondary lymphedema, according to the companies.